Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute
31 January 2019
Cullinan Oncology, LLC and The Wistar Institute today announced an agreement to accelerate the development of VK-2019, a novel EBNA1 (Epstein-Barr Nuclear Antigen 1) inhibitor discovered by The Wis
